A drug currently FDA-approved for use in diabetes shows some protective effects in the brains of patients with relapsing remitting multiple sclerosis, researchers at the University of Illinois at Chicago College of Medicine report in a study currently available online in the Journal of Neuroimmunology.
Keywords: University of Illinois, pioglitazone, Actos, neuronal survival, clinical trial.
Source Medical News Today
Full text Link: http://www.medicalnewstoday.com/articles/151448.php
Note: Currently in France is running a clinical trial with Pioglitazone for patients with FA.
( http://www.clinicaltrials.gov/ct2/show/NCT00811681?term=friedreich )
Thursday, May 28, 2009
Subscribe to:
Posts (Atom)
